A Phase 3, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Navitoclax Plus Ruxolitinib Versus Best Available Therapy In Patients With Relapsed/Refractory Myelofibrosis (Transform-2)

Background: Myelofibrosis (MF) is a rare myeloproliferative neoplasm with limited treatment options and a poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure, most patients remain ineligible; other therapies, including approved JAK inhibitors (JAKi), do not control the broad array of manifestations associated with MF.